Price Chart
Insider Transactions
No insider transactions in the last 90 days.
Score Breakdown
| Component | Points | Max |
|---|---|---|
| Conviction (unique buyers) ✓ FREE PREVIEW | 30 | 30 |
| Buy/sell ratio | 20 | |
| Dollar value | 25 | |
| Lobbying activity | 15 | |
| Contract wins | 10 | |
| Insider track record | 10 | |
| Private placements | 8 | |
| Confluence bonus | 10 | |
| Cluster timing (velocity) | 10 | |
| Buy/sell reversal pattern | 8 | |
| Total | 0 | 100 |
Lobbying Registrations
No active OCL lobbying registrations in the last 90 days.
Analyst plan →
Government Contract Wins
No government contract wins in the last 90 days.
Analyst plan →
Private Placements
Private placement history, deal size, and lock-up expiry tracking.
Analyst plan →
Indigenous Consultation
No Indigenous consultation records on file for ARCH.
SEDAR+ Filings
Form55 monitors SEDAR+ filing alerts and newswire announcements for Technical Reports and material changes.
Search SEDAR+ →
Short Interest
Shares short
40,552
Net change
+20,362
(+100.9%)
Short interest rose 101% since the prior report.
History
Jun 30:
40,552
Jun 15:
20,190
May 31:
17,249
May 15:
16,978
Apr 30:
23,008
Apr 15:
27,106
Aggregate short position from CIRO's Consolidated Short Position Report (published twice monthly).
Clinical Trials
| Phase | Status | Trial |
|---|---|---|
| P2 | Recruiting | LSALT Peptide for Prevention or Attenuation of Acute Kidney Injury (AK |
| P2 | Completed | LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in P |
| EARLY_P1 | Completed | A Phase I Study to Evaluate LSALT Peptide |
Trials where this company is the lead sponsor (ClinicalTrials.gov). Phase advances, completions and
terminations are material catalysts for clinical-stage companies — not investment advice.
Government Grants & Funding
| Program / Agreement | Amount |
|---|---|
| Industrial Research Assistance Program – Contributions to Firms Contribution | $4.0M |
| Industrial Research Assistance Program – Contributions to Firms Contribution | $4.0M |
| SIF Stream 1- R&D Contribution | $6.2M |
| SIF Stream 1- R&D Contribution | $5.9M |
| SIF Stream 1- R&D Contribution | $5.4M |
| SIF Stream 1- R&D Contribution | $5.4M |
| Industrial Research Assistance Program – Contributions to Firms Contribution | $200K |
| Industrial Research Assistance Program – Contributions to Firms Contribution | $200K |
| — Contribution | $91K |
| — Contribution | $107K |
Federal grants & contributions disclosed by the Government of Canada (Proactive Disclosure), matched to
this issuer by legal name. Government funding can be a pre-revenue validation and capital signal. Display-only
context, not a Confluence Score input.